UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)*

iTeos Therapeutics, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 46565G104 (CUSIP Number)

Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

> October 13, 2021 (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	USIP No. 46565G104							
1.	Name of	Repo	rting Persons.					
	MPM B	ioVent	ures 2014, L.P.					
2.	Check th	Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a)	(b) 🗵	3 (1)					
3.	SEC US	E ONI	LY					
4.	Sourco	f Fund	de (See Instructione)					
4.	Source of Funds (See Instructions)							
	WC							
5.	Check if	Discl	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)					
6.	6. Citizenship or Place of Organization		Place of Organization					
	Delawar	e						
		7.	Sole Voting Power					
Nu	umber of		1,771,303					
	Shares	8.	Shared Voting Power					
	neficially							
	wned by Each	9.	0 Sole Dispositive Power					
Re	eporting	5.						
	Person		1,771,303					
	With:	10.	Shared Dispositive Power					
			0					
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person					
	1,771,30	3						
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)					
13.	Percent	of Clas	ss Represented by Amount in Row (11)					
10.								
14.	5.0%(2)	Report	ting Person (See Instructions)					
14,	Type of	repon						
	PN							

- (1) This schedule is filed by MPM BioVentures 2014, L.P. ("BV 2014"), MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), MPM Asset Management Investors BV2014 LLC ("AM BV2014 LLC"), MPM BioVentures 2018, L.P. ("BV 2018"), MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), MPM Asset Management Investors BV2018 LLC ("AM BV2018 LLC"), UBS Oncology Impact Fund L.P. ("UBS Oncology"), MPM BioVentures 2014 GP LLC ("BV 2014 GP"), MPM BioVentures 2014 LLC ("BV 2014 LLC"), MPM BioVentures 2018 GP LLC ("BV 2018 GP"), MPM BioVentures 2018 LLC ("BV 2018 LLC"), Oncology Impact Fund (Cayman) Management LP ("Oncology Cayman") and BioImpact Capital LLC ("BioImpact") (collectively, the "MPM Entities") and Ansbert Gadicke, Luke Evnin, Todd Foley and Edward Hurwitz (collectively, the "Listed Persons" and together with the MPM Entities, the "Filing Persons"). The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.
- (2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of iTeos Therapeutics, Inc. (the "Issuer"), as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

00011	NO. 4656	50104		
1.	Name of	Repo	rting Persons.	
	MPM B	ioVent	ures 2014 (B), L.P.	
2.			ropriate Box if a Member of a Group (See Instructions)	
	(a)	(b) 🗵		
3.	SEC US	E ONI	Y	
4.	4. Source of Funds (See Instructions)			
	WC			
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	6. Citizenship or Place of Organization			
	Delawar	e		
		7.	Sole Voting Power	
Ni	umber of		107,713	
9	Shares	8.	Shared Voting Power	
	neficially wned by		0	
	Each	9.	Sole Dispositive Power	
	eporting Person		107,713	
	With:	10.	Shared Dispositive Power	
			0	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	107,713			
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	ss Represented by Amount in Row (11)	
	0.3%(2)			
14.			ing Person (See Instructions)	
	DN			
	PN			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

1.	Name of	f Repoi	rting Persons.
	MPM A	sset M	anagement Investors BV2014 LLC
2.	Check th	ne App	ropriate Box if a Member of a Group (See Instructions)
	(a)	(b) 🗵] (1)
3.	SEC US	E ONI	X
4.	4. Source of Funds (See Instructions)		
	WC		
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6.	Citizens	hip or 1	Place of Organization
	Delawar	re 7.	Sole Voting Power
		/.	Sole voting i ower
Nu	imber of		60,967
	Shares	8.	Shared Voting Power
	neficially wned by		0
	Each	9.	Sole Dispositive Power
	eporting		-
	Person With:		60,967
	vviui:	10.	Shared Dispositive Power
			0
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person
	60,967		
12.		the Ag	ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13.	Percent	of Clas	ss Represented by Amount in Row (11)
1.4	0.2%(2)		
14.	Type of	Keport	ing Person (See Instructions)
	00		

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSH	USIP No. 46565G104				
1.	Name of	Repo	rting Persons.		
	MPM B	ioVent	ures 2018, L.P.		
2.			propriate Box if a Member of a Group (See Instructions)		
	(a)	(b) 🗵			
3.	SEC US	E ONI	LY		
4.	Source of Funds (See Instructions)				
	WC				
5.	Check if	Discl	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	6. Citizenship or Place of Organization				
	Delawar				
		7.	Sole Voting Power		
Nı	umber of		1,118,717		
	Shares	8.	Shared Voting Power		
	neficially wned by		0		
	Each	9.	Sole Dispositive Power		
	eporting Person				
	With:	10.	1,118,717 Shared Dispositive Power		
		101			
11	A				
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person		
	1,118,71				
12.	Check if	the A	ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percent	of Clas	ss Represented by Amount in Row (11)		
	3.2%(2)				
14.			ting Person (See Instructions)		
	PN				
	117				

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

00011	NO. 4656	50104		
1.	Name of	Repo	rting Persons.	
	MPM B	ioVent	ures 2018 (B), L.P.	
2.		ne App (b) ⊠	ropriate Box if a Member of a Group (See Instructions)	
	(a)	(0) 🗠		
3.	SEC US	E ONI	LY	
4.	4. Source of Funds (See Instructions)			
	WC			
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	6. Citizenship or Place of Organization			
	Delawar	e		
		7.	Sole Voting Power	
Ni	umber of		54,213	
	Shares	8.	Shared Voting Power	
	neficially wned by		0	
	Each	9.	Sole Dispositive Power	
	eporting Person		54,213	
	With:	10.	Shared Dispositive Power	
			0	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	54,213			
12.	Check if	the A	ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	as Represented by Amount in Row (11)	
	0.2%(2)			
14.			ing Person (See Instructions)	
	PN			
	LIN			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

2. Check the Approp (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (WC Source of Disclosu	agement Investors BV2018 LLC priate Box if a Member of a Group (See Instructions) 1)
2. Check the Approp (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (WC 5. Check if Disclosu	1) (See Instructions)
2. Check the Approp (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (WC Source of Disclosu	1) (See Instructions)
3. SEC USE ONLY 4. Source of Funds (WC WC 5. Check if Disclosu	(See Instructions)
4. Source of Funds (WC Source of Disclosu	(See Instructions)
WC 5. Check if Disclosu	
5. Check if Disclosu	ure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
	ure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6 Citizonchin or Dis	
0. Citizensinp of Pia	ace of Organization
Delaware	
7.	Sole Voting Power
Number of	22,078
Shares 8.	Shared Voting Power
Beneficially Owned by	0
	Sole Dispositive Power
Reporting	
	22,078 Shared Dispositive Power
10.	Shared Dispositive Power
	0
11. Aggregate Amou	nt Beneficially Owned by Each Reporting Person
22,078	
-	regate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class I	Represented by Amount in Row (11)
0.1%(2) 14. Type of Reporting	g Person (See Instructions)
	א דרוסטו (סבר ווסונתכווטווס)
00	

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

1.	Name of	Repo	rting Persons.	
	UBS On	cology	7 Impact Fund, L.P.	
2.			ropriate Box if a Member of a Group (See Instructions)	
	(a)	(b) 🗵		
3.	SEC US	E ONI	Y	
4.	4. Source of Funds (See Instructions)			
	WC			
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	6. Citizenship or Place of Organization			
	Delawar	e		
		7.	Sole Voting Power	
Nı	mber of		2,002,223	
	Shares	8.	Shared Voting Power	
	neficially			
	wned by		0	
	Each	9.	Sole Dispositive Power	
	eporting Person		2,002,223	
	With:	10.	Shared Dispositive Power	
		10.		
			0	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	2,002,22			
12.	Check if	the Ag	ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	ss Represented by Amount in Row (11)	
	5.7%(2)			
14.		Report	ing Person (See Instructions)	
	PN			
	TIA			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

COSH	INO. 4050	00101					
1.	Name of	Repo	rting Persons.				
	MPM B	ioVent	ures 2014 GP LLC				
2.			ropriate Box if a Member of a Group (See Instructions)				
	(a)	(b) 🗵					
3.	SEC US	E ONI	_Y				
4.	Source o	Source of Funds (See Instructions)					
	WC						
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)				
6.	5. Citizenship or Place of Organization						
	Delawar	e					
		7.	Sole Voting Power				
Nı	umber of		0				
	Shares	8.	Shared Voting Power				
	neficially						
	wned by		1,879,016(2)				
	Each eporting	9.	Sole Dispositive Power				
	Person		0				
	With:	10.	Shared Dispositive Power				
		101					
			1,879,016(2)				
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person				
	4 0 7 0 0 4						
10	1,879,01						
12.	CHECK II	ine A	ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	Percent	of Clas	ss Represented by Amount in Row (11)				
	5.3%(3)						
14.	Type of	Report	ing Person (See Instructions)				
	00						

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,771,303 shares held by BV 2014 and 107,713 shares held by BV 2014(B). BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B).

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

com	NO. 4656	50104		
1.	Name of	Repo	rting Persons.	
	MPM B	ioVent	ures 2014 LLC	
2.			ropriate Box if a Member of a Group (See Instructions)	
	(a)	(b) 🗵		
3.	SEC US	E ONI	Y	
4.	4. Source of Funds (See Instructions)			
	WC			
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	Citizenship or Place of Organization			
	Delawar	e		
		7.	Sole Voting Power	
Ni	umber of		0	
	Shares	8.	Shared Voting Power	
	neficially wned by		1,939,983(2)	
	Each	9.	Sole Dispositive Power	
	eporting			
	Person With:	10		
	***	10.	Shared Dispositive Power	
			1,939,983(2)	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	1,939,98	3(2)		
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	ss Represented by Amount in Row (11)	
14.	5.5%(3) Type of		ing Person (See Instructions)	
	-JF- 01	-r -r -		
	00			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,771,303 shares held by BV 2014, 107,713 shares held by BV 2014(B) and 60,967 shares held by AM BV2014 LLC. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014 LLC

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

	NO. 4050	0010.		
1.	Name of	Repo	rting Persons.	
	MPM B	ioVenti	ures 2018 GP LLC	
2.			ropriate Box if a Member of a Group (See Instructions)	
	(a)	(b) 🗵		
3.	SEC US	E ONI	Y	
4.	Source of	of Fund	ls (See Instructions)	
	WC			
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	6. Citizenship or Place of Organization			
	Delawar	e		
		7.	Sole Voting Power	
Nu	umber of		0	
	Shares	8.	Shared Voting Power	
Ber	Beneficially			
	wned by		1,172,930(2)	
	Each	9.	Sole Dispositive Power	
	eporting Person		0	
	With:	10.	Shared Dispositive Power	
	_		1,172,930(2)	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	1,172,93	80(2)		
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	ss Represented by Amount in Row (11)	
	3.3%(3)			
14.	Type of	Report	ing Person (See Instructions)	
	00			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,118,717 shares held by BV 2018 and 54,213 shares held by BV 2018(B). BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B).

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

COOL	No. 4656	50104	*	
1.	Name of	Repo	rting Persons.	
	MPM B	ioVent	ures 2018 LLC	
2.	Check th	ne App	propriate Box if a Member of a Group (See Instructions)	
	(a)	(b) 🗵	3 (1)	
3.	SEC US	E ONI	LY	
4.	I. Source of Funds (See Instructions)			
	WC			
5.	Check if	Discl	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6.	Citizens	hip or	Place of Organization	
	Delawar	e		
		7.	Sole Voting Power	
Ni	umber of		0	
9	Shares	8.	Shared Voting Power	
	neficially wned by		1,195,008(2)	
	Each	9.	Sole Dispositive Power	
Re	eporting			
	Person With:		0	
	••1011.	10.	Shared Dispositive Power	
			1,195,008(2)	
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person	
	1,195,00)8(2)		
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)	
13.	Percent	of Clas	ss Represented by Amount in Row (11)	
14.	3.4%(3) Type of		ting Person (See Instructions)	
		•		
	00			

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,118,717 shares held by BV 2018, 54,213 shares held by BV 2018(B) and 22,078 shares held by AM BV2018 LLC. BV 2018 GP and BV 2018 LLC are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018 LLC.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

1. Name of Reporting Persons. Oncology Impact Fund (Cayman) Management LP 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Xource of Shares Beneficially Output Shares Beneficially Young Sole Dispositive Power Qoung Dispositive Power 					
2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Xource of Shares Beneficially Owned by Each Sole Dispositive Power 	Name of Reporting Persons.				
2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) ⊠ (1) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Xoure of Shares Beneficially Owned by Each Sole Dispositive Power 					
3. SEC USE ONLY 4. Source of Funds (See Instructions) WC . 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware 7. Sole Voting Power Shares 8. Beneficially 0 9. Sole Dispositive Power					
4. Source of Funds (See Instructions) WC					
WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware 7. Sole Voting Power 2,002,223(2) 2,002,223(2) Shares 8. Shared Voting Power Beneficially 0 Owned by 0 Each 9. Sole Dispositive Power					
WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware 7. Sole Voting Power 2,002,223(2) Shares Beneficially Owned by 0 Each 9. Sole Dispositive Power					
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware 7. Sole Voting Power 2,002,223(2) Shares 8. Beneficially 0 Owned by 0 Each 9. Sole Dispositive Power					
6. Citizenship or Place of Organization Delaware 7. Sole Voting Power 2,002,223(2) Shares 8. Beneficially 0 Owned by 0 Each 9. Sole Dispositive Power					
Delaware Number of Shares 7. Sole Voting Power 8. Shared Voting Power Beneficially Owned by Each 0 9. Sole Dispositive Power					
Number of Shares 7. Sole Voting Power 2,002,223(2) 2,002,223(2) Shares 8. Shared Voting Power Beneficially Owned by Each 0 9. Sole Dispositive Power					
Number of Shares 2,002,223(2) Beneficially Owned by 0 Each 9. Sole Dispositive Power					
Shares 8. Shared Voting Power Beneficially 0 Owned by 0 Each 9. Sole Dispositive Power					
Shares 8. Shared Voting Power Beneficially 0 Owned by 0 Each 9. Sole Dispositive Power					
Owned by 0 Each 9. Sole Dispositive Power					
Each 9. Sole Dispositive Power					
Person 2,002,223(2) With: 10 Shared Dispositive Power					
With: 10. Shared Dispositive Power					
0					
11. Aggregate Amount Beneficially Owned by Each Reporting Person					
2,002,223(2)					
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)					
13. Percent of Class Represented by Amount in Row (11)					
5.7%(3) 14. Type of Reporting Person (See Instructions)					
PN					

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Consists of shares held by UBS Oncology. BioImpact is the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSIF	P No. 4656	5G104	ł						
1.	Name of	Name of Reporting Persons.							
	BioImpa	act Cap	pital LLC						
2.	Check the Appropriate Box if a Member of a Group (See Instructions)								
	(a)	(b) 🗵							
3.	SEC US	E ONI	LY						
4.	Source o	of Fund	ds (See Instructions)						
	WC								
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)						
6.	Citizenship or Place of Organization								
	Delawar	e							
		7.	Sole Voting Power						
Ni	umber of		2,002,223(2)						
5	Shares	8.	Shared Voting Power						
	neficially		0						
	wned by Each	9.	Sole Dispositive Power						
Re	eporting	51							
	Person		2,002,223(2)						
	With:	10.	Shared Dispositive Power						
			0						
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person						
	2,002,22	23(2)							
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)						
13.	Percent of Class Represented by Amount in Row (11)								
	5.7%(3)								
14.			ting Person (See Instructions)						
	00								
	00								

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Consists of shares held by UBS Oncology. BioImpact is the general partner Oncology (Cayman), the General Partner of UBS Oncology.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSIF	No. 4656	5G104	•						
1.	Name of Reporting Persons.								
	Ansbert	Gadicl	xe						
2.	Check the Appropriate Box if a Member of a Group (See Instructions)								
	(a)	(b) 🗵	3 (1)						
3.	SEC US	E ONI	LY						
4.	Source of	of Fund	ds (See Instructions)						
	00								
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)						
6.	Citizens	hip or	Place of Organization						
	United S	tates							
		7.	Sole Voting Power						
Nu	mber of		0						
9	Shares	8.	Shared Voting Power						
	neficially wned by		5,137,214(2)						
	Each	9.	Sole Dispositive Power						
	eporting								
	Person With:	10.	0 Shared Dispositive Power						
		10.	Shaled Dispositive Power						
			5,137,214(2)						
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person						
	5,137,21	.4(2)							
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)						
13.	Percent of Class Represented by Amount in Row (11)								
	14.6%(3)							
14.			ting Person (See Instructions)						
	IN								
, ļ									

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,771,303 shares held by BV 2014, 107,713 shares held by BV 2014(B), 60,967 shares held by AM BV 2014 LLC, 1,118,717 share held by BV 2018, 54,213 shares held by BV 2018(B), 22,078 shares held by AM BV 2018 LLC and 2,002,223 shares held by UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV2018 LLC and the managing partner of BioImpact.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSIF	No. 4656	5G104							
1.	Name of	Name of Reporting Persons.							
	Luke Ev	nin							
2.		Check the Appropriate Box if a Member of a Group (See Instructions)							
	(a)	(b) 🗵							
3.	SEC US	E ONI	_Y						
4.	Source of	of Fund	ds (See Instructions)						
	00								
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)						
6.	Citizens	hip or l	Place of Organization						
	United S	States							
		7.	Sole Voting Power						
			0						
	imber of	8.	Shared Voting Power						
	Shares neficially	0.	Shared voting rower						
	wned by		3,134,991(2)						
	Each	9.	Sole Dispositive Power						
	eporting								
	Person With:		0						
	with:	10.	Shared Dispositive Power						
			3,134,991(2)						
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person						
	3,134,99	1(7)							
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)						
13.	Percent	of Clas	ss Represented by Amount in Row (11)						
	8.9%(3)								
14.	Type of	Report	ing Person (See Instructions)						
	IN								

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,771,303 shares held by BV 2014, 107,713 shares held by BV 2014(B), 60,967 shares held by AM BV 2014 LLC, 1,118,717 share held by BV 2018, 54,213 shares held by BV 2018(B) and 22,078 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSII	NO. 4656	56104	•							
1.	Name of	Repo	rting Persons.							
	Todd Fo	Todd Foley								
2.		Check the Appropriate Box if a Member of a Group (See Instructions)								
	(a)	(0) 🗠								
3.	SEC US	E ONI	LY							
4.	Source o	of Fund	ds (See Instructions)							
	00									
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)							
6.	Citizens	hip or	Place of Organization							
	United S	tates								
		7.	Sole Voting Power							
Ni	mber of		0							
9	Shares	8.	Shared Voting Power							
	neficially wned by		3,134,991(2)							
	Each eporting	9.	Sole Dispositive Power							
]	Person		0							
	With:	10.	Shared Dispositive Power							
			3,134,991(2)							
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person							
	3,134,99									
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)									
13.	Percent	of Clas	ss Represented by Amount in Row (11)							
	8.9%(3)									
14.		Report	ting Person (See Instructions)							
	IN									

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,771,303 shares held by BV 2014, 107,713 shares held by BV 2014(B), 60,967 shares held by AM BV 2014 LLC, 1,118,717 share held by BV 2018, 54,213 shares held by BV 2018(B) and 22,078 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

CUSIE	No. 4656	5G104						
1.	Name of Reporting Persons.							
	Edward	Hurwi	tz					
2.	Check the Appropriate Box if a Member of a Group (See Instructions)							
	(a)	(b) 🗵						
3.	SEC US	E ONI	LY					
4.	Source of	of Fund	ds (See Instructions)					
	00							
5.	Check if	Disclo	osure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)					
6.	Citizenship or Place of Organization							
	United S	States						
		7.	Sole Voting Power					
N	umber of		0					
5	Shares	8.	Shared Voting Power					
	neficially		1 105 000/2)					
	wned by Each	9.	1,195,008(2) Sole Dispositive Power					
Re	eporting	5.						
	Person		0					
	With:	10.	Shared Dispositive Power					
			1,195,008(2)					
11.	Aggrega	te Am	ount Beneficially Owned by Each Reporting Person					
	1,195,00)8(2)						
12.			ggregate Amount in Row (11) Excludes Certain Shares (See Instructions)					
13.	Percent	of Clas	ss Represented by Amount in Row (11)					
	3.4%(3)							
14.			ing Person (See Instructions)					
	IN							
Į								

(1) This Schedule is filed by the MPM Entities and the Listed Persons. The MPM Entities and the Listed Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Includes 1,118,717 shares held by BV 2018, 54,213 shares held by BV 2018(B) and 22,078 shares held by AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

(3) This percentage is calculated based upon 35,209,755 outstanding shares of common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

This Amendment No. 2 to Schedule 13D ("Amendment No. 2") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of iTeos Therapeutics Inc. (the "Issuer"), as filed with the Securities and Exchange Commission (the "SEC") on August 7, 2020 and , as amended by Amendment No. 1 filed September 21, 2021 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales and distributions in kind of the Issuer's Common Stock by certain Filing Persons.

Items 4, 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 2 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

Item 4. Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

The MPM Entities sold an aggregate of 438,998 shares of Common Stock in open market transactions from September 21, 2021 through October 18, 2021 for aggregate gross proceeds of \$12,003,881.

Item 5. Interest in Securities of the Issuer

(a) - (b) The following information with respect to the ownership of the Common Stock of the Issuer by the Filing Persons is provided as of October 18, 2021:

Reporting Person	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (1)
BV 2014	1,771,303	1,771,303	0	1,771,303	0	1,771,303	5.0%
BV 2014(B)	107,713	107,713	0	107,713	0	107,713	0.3%
AM BV 2014 LLC	60,967	60,967	0	60,967	0	60,967	0.2%
BV 2018	1,118,717	1,118,717	0	1,118,717	0	1,118,717	3.2%
BV 2018(B)	54,213	54,213	0	54,213	0	54,213	0.2%
AM BV 2018 LLC	22,078	22,078	0	22,078	0	22,078	0.1%
UBS Oncology	2,002,223	2,002,223	0	2,002,223	0	2,002,223	5.7%
BV 2014 GP(2)	0	0	1,879,016	0	1,879,016	1,879,016	5.3%
BV 2014 LLC(3)	0	0	1,939,983	0	1,939,983	1,939,983	5.5%
BV 2018 GP(4)	0	0	1,172,930	0	1,172,930	1,172,930	3.3%
BV 2018 LLC(5)	0	0	1,119,008	0	1,119,008	1,119,008	3.4%
Oncology Cayman(6)	0	0	2,002,223	0	2,002,223	2,002,223	5.7%
BioImpact(6)	0	0	2,002,223	0	2,002,223	2,002,223	5.7%
Ansbert Gadicke(7)	0	0	5,137,214	0	5,137,214	5,137,214	14.6%

1							
Luke Evnin(8)	0	0	3,134,991	0	3,134,991	3,134,991	8.9%
Todd Foley(8)	0	0	3,134,991	0	3,134,991	3,134,991	8.9%
Edward Hurwitz(9)	0	0	1,195,008	0	1,195,008	1,195,008	3.4%
(1) This percentage is calculated based upon 25 200 755 outstanding	common stock of the Issuer	ac di	icclosed in th	o Icc		dry Donowt on	Form

(1) This percentage is calculated based upon 35,209,755 outstanding common stock of the Issuer, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 11, 2021.

(2) Includes securities held by BV 2014 and BV 2014(B). BV 2014 GP is the direct general partner of BV 2014 and BV 2014(B).

(3) Includes securities held by BV 2014, BV2014(B) and AM BV 2014 LLC. BV 2014 LLC is the indirect general partner of BV 2014 and BV 2014(B) and the manager of AM BV 2014 LLC.

(4) Includes securities held by BV 2018 and BV 2018(B). BV 2018 GP is the direct general partner of BV 2018 and BV 2018(B).

(5) Includes securities held by BV 2018, BV 2018(B) and AM BV 2018 LLC. BV 2018 LLC is the indirect general partner of BV 2018 and BV 2018(B) and the manager of AM BV 2018 LLC.

- (6) Includes shares held by UBS Oncology. BioImpact is the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.
- (7) Includes securities held by BV 2014, BV 2014(B), AM BV 2014 LLC, BV 2018, BV 2018(B), AM BV 2018 LLC and UBS Oncology. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC and the managing partner of BioImpact.
- (8) Includes securities held by BV 2014, BV 2014(B), AM BV 2014 LLC, BV 2018, BV 2018(B), and AM BV 2018 LLC. The Reporting Person is a managing director of BV 2014 LLC and BV 2018 LLC.
- (9) Includes shares held by BV 2018, BV 2018(B) and AM BV 2018 LLC. The Reporting Person is a managing director of BV 2018 LLC.

Each Filing Person disclaims membership in a "group." Each Filing Person also disclaims beneficial ownership of any shares of the Issuer, except for the shares set forth in the table above next to the respective Filing Person's name in subsection (b) of this Item 5.

The Reporting Persons sold the following Common Stock in the open market in the sixty days preceding the date of this filing:

Date of Sale	Price Range	Average Price	Sold by BV 2014	Sold by AM BV 2014 LLC	Sold by BV 2018	Sold by AM BV 2018 LLC	Sold by UBS Oncology
9/7/2021	\$ 28.89-\$29.64	\$29.18	18,156	625	11,467	226	20,522
9/8/2021	\$ 28.02-\$29.01	\$28.61	6,644	229	4,196	83	7,511
9/8/2021	\$ 29.04-\$29.21	\$29.10	560	19	354	7	633
9/9/2021	\$ 28.29-\$29.27	\$28.97	13,539	466	8,551	169	15,303
9/10/2021	\$27.455-\$28.45	\$27.86	4,027	139	2,544	50	4,553
9/10/2021	\$ 28.46-\$28.91	\$28.73	4,034	139	2,547	51	4,559
9/13/2021	\$ 27.17-\$27.99	\$27.64	12,740	439	8,046	159	14,401
9/14/2021	\$ 26.91-\$27.90	\$27.50	10,687	368	6,750	133	12,080
9/14/2021	\$27.92-\$28.055	\$27.99	2,159	74	1,363	27	2,440
9/15/2021	\$ 27.12-\$28.11	\$27.79	13,770	474	8,697	172	15,564
9/15/2021	\$ 28.13-\$28.19	\$28.15	591	20	373	7	668
9/16/2021	\$27.885-\$28.69	\$28.47	12,662	436	7,997	158	14,312
9/17/2021	\$ 28.50-\$29.11	\$28.82	27,226	937	17,195	340	30,775
9/20/2021	\$26.535-\$27.52	\$27.03	6,317	217	3,990	78	7,141
9/20/2021	\$ 27.53-\$28.39	\$27.84	8,163	281	5,156	101	9,229
9/21/2021	\$ 26.98-\$27.72	\$27.47	11,698	403	7,388	146	13,223
9/22/2021	\$ 27.03-\$27.75	\$27.54	8,516	293	5,379	106	9,627

9/23/2021	\$ 27.25-\$28.24	\$ 27.96	21,575	743	13,626	269	24,387
9/23/2021	\$ 28.26-\$28.46	\$ 28.38	427	15	270	5	483
9/24/2021	\$ 27.39-\$28.26	\$ 27.81	2,927	101	1,849	36	3,308
9/27/2021	\$ 26.95-\$27.40	\$ 27.09	6,926	238	4,375	86	7,830
9/28/2021	\$ 26.95-\$27.10	\$ 27.00	11,447	394	7,230	143	12,940
9/30/2021	\$ 26.955-\$27.05	\$ 27.00	1,366	47	862	17	1,544
10/1/2021	\$ 26.95-\$27.07	\$ 27.00	4,084	141	2,579	51	4,616
10/4/2021	\$ 26.95-\$27.19	\$ 27.06	12,339	425	7,793	154	13,948
10/7/2021	\$ 26.95-\$27.07	\$ 27.00	684	24	432	9	773
10/8/2021	\$ 26.97-\$27.035	\$ 27.01	1,210	42	765	15	1,368
10/11/2021	\$ 26.95-\$27.53	\$ 27.24	29,081	1,001	18,367	363	32,872
10/12/2021	\$ 26.95-\$27.28	\$ 27.09	5,077	175	3,206	63	5,739
10/13/2021	\$ 26.95-\$27.335	\$ 27.13	12,469	429	7,875	156	14,094
10/14/2021	\$ 26.95-\$27.84	\$ 27.30	16,277	560	10,280	203	18,399
10/15/2021	\$ 26.97-\$27.955	\$ 27.53	5,298	182	3,347	66	5,989
10/15/2021	\$ 27.97-\$28.07	\$ 28.01	1,215	42	767	15	1,374
10/18/2021	\$ 26.96-\$27.94	\$ 27.14	3,676	125	2,321	45	4,153
			297,567	10,243	187,937	3,709	336,358

The information provided and incorporated by reference in Item 3 and Item 6 is hereby incorporated by reference in this Item 5.

(d) Inapplicable.

(e) Inapplicable.

Item 7. Material to Be Filed as Exhibits

C. Agreement regarding filing of joint Schedule 13D.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 18, 2021

MPM BIOVENTURES 2014, L.P.

By:	MPM BioVentures 2014 GP LLC,
	its General Partner
By:	MPM BioVentures 2014 LLC,
	Its Managing Member

/s/ Luke Evnin By:

Name: Luke Evnin Title: Managing Director

MPM BIOVENTURES 2014 (B), L.P.

By: MPM BioVentures 2014 GP LLC, its General Partner MPM BioVentures 2014 LLC, By: Its Managing Member

By: /s/ Luke Evnin

Luke Evnin Name:

Title: Managing Director

MPM ASSET MANAGEMENT INVESTORS BV 2014 LLC

By:	MPM BioVentures 2014 LLC,
	Its Manager

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2014 GP LLC

By: MPM BioVentures 2014 LLC, Its Managing Member

By: /s/ Luke Evnin

Luke Evnin Name:

Title: Managing Director

MPM BIOVENTURES 2014 LLC

By:	/s/ Luke Evnin
Name:	Luke Evnin
Title:	Managing Director

MPM BIOVENTURES 2018, L.P.

By:	MPM BioVentures 2018 GP LLC,
	its General Partner
By:	MPM BioVentures 2018 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2018 (B), L.P.

By:	MPM BioVentures 2018 GP LLC,
	its General Partner
By:	MPM BioVentures 2018 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM ASSET MANAGEMENT INVESTORS BV 2018 LLC

By:	MPM BioVentures 2018 LLC,
	Its Manager

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2018 GP LLC

By: MPM BioVentures 2018 LLC, Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin Title: Managing Director

MPM BIOVENTURES 2018 LLC

By:/s/ Luke EvninName:Luke EvninTitle:Managing Director

UBS ONCOLOGY IMPACT FUND, L.P.

By:	Oncology Impact Fund (Cayman) Management L.P.,
	its General Partner
By:	BioImpact Capital LLC
	Its General Partner

By: /s/ Ansbert Gadicke Name: Ansbert Gadicke

Title: Managing Partner

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

By: BioImpact Capital LLC

By: /s/ Ansbert Gadicke

Name:Ansbert GadickeTitle:Managing Partner

BIOIMPACT CAPITAL LLC

5	/s/ Ansbert Gadicke Ansbert Gadicke Managing Partner	
5	/s/ Todd Foley Todd Foley	
	/s/ Luke Evnin	
Name:	Luke Evnin	
By:	/s/ Ansbert Gadicke	
Name:	Ansbert Gadicke	
By:	/s/ Edward Hurwitz	
Name:	Edward Hurwitz	

Schedule I

General Partners/Members

Ansbert Gadicke c/o MPM Asset Management 450 Kendall Street Cambridge, MA 02142 Principal Occupation: Managing director of MPM BioVentures 2014 LLC, MPM BioVentures 2018 LLC and managing partner of BioImpact Capital LLC. Citizenship: USA

Luke Evnin c/o MPM Asset Management 450 Kendall Street Cambridge, MA 02142 Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC. Citizenship: USA

Todd Foley c/o MPM Asset Management 450 Kendall Street Cambridge, MA 02142 Principal Occupation: Managing director of MPM BioVentures 2014 LLC and MPM BioVentures 2018 LLC. Citizenship: USA

Edward Hurwitz c/o MPM Asset Management 450 Kendall Street Cambridge, MA 02142 Principal Occupation: Managing director of MPM BioVentures 2018 LLC. Citizenship: USA

Exhibit Index

C. Agreement regarding filing of joint Schedule 13D.

Exhibit C

Joint Filing Statement

I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of iTeos Therapeutics, Inc. is filed on behalf of each of the undersigned.

Date: October 18, 2021

MPM BIOVENTURES 2014, L.P.

- By: MPM BioVentures 2014 GP LLC,
- its General Partner MPM BioVentures 2014 LLC, By:
- Its Managing Member
- By: /s/ Luke Evnin
- Name: Luke Evnin Title:
- Managing Director

MPM BIOVENTURES 2014 (B), L.P.

By:	MPM BioVentures 2014 GP LLC,
	its General Partner
By:	MPM BioVentures 2014 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM ASSET MANAGEMENT INVESTORS BV 2014 LLC

By:	MPM BioVentures 2014 LLC,
	Its Manager

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2014 GP LLC

By: MPM BioVentures 2014 LLC, Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin Title: Managing Director

MPM BIOVENTURES 2014 LLC

By:	/s/ Luke Evnin
Name:	Luke Evnin
Title:	Managing Director

MPM BIOVENTURES 2018, L.P.

By:	MPM BioVentures 2018 GP LLC,
	its General Partner
By:	MPM BioVentures 2018 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2018 (B), L.P.

By:	MPM BioVentures 2018 GP LLC,
	its General Partner
By:	MPM BioVentures 2018 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM ASSET MANAGEMENT INVESTORS BV 2018 LLC

By:	MPM BioVentures 2018 LLC,
	Its Manager

By: /s/ Luke Evnin

Name:Luke EvninTitle:Managing Director

MPM BIOVENTURES 2018 GP LLC

By:	MPM BioVentures 2018 LLC,
	Its Managing Member

By: /s/ Luke Evnin

Name: Luke Evnin

Title: Managing Director

MPM BIOVENTURES 2018 LLC

By:	/s/ Luke Evnin
Name:	Luke Evnin
Title:	Managing Director

UBS ONCOLOGY IMPACT FUND, L.P.

By:	Oncology Impact Fund (Cayman) Management L.P.,
	its General Partner
By:	BioImpact Capital LLC
	Its General Partner

By:/s/ Ansbert GadickeName:Ansbert GadickeTitle:Managing Partner

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

By: BioImpact Capital LLC

By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke
Title:	Managing Partner

BIOIMPACT CAPITAL LLC

By:	/s/ Ansbert Gadicke	
Name:	Ansbert Gadicke	
Title:	Managing Partner	
By:	/s/ Todd Foley	
Name:	Todd Foley	
D	/s/I siles Erenin	
ву:	/s/ Luke Evnin	
Name:	Luke Evnin	
By:	/s/ Ansbert Gadicke	
Name:	Ansbert Gadicke	
By:	/s/ Edward Hurwitz	
5		
Name:	Edward Hurwitz	